v3.26.1
Unaudited Condensed Consolidated Interim Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Current Assets    
Cash and cash equivalents $ 1,168 $ 4,360
Restricted cash 595
Property and equipment, held for sale 157
Other current assets 1,875 463
Total Current assets 3,043 5,575
Non-current Assets    
In-process Research and development (“IPR&D”) asset 208 208
Total assets 3,251 5,783
Current Liabilities    
Trade account payables 720 3,120
Balance due Biomx Ltd 1,254
Current portion of lease liabilities 1,436
Other account payables 473 1,823
Total current liabilities 2,447 6,379
Non-current Liabilities    
Warrants 1,685 706
Total non-current liabilities 1,685 706
Total liabilities 4,132 7,085
Capital deficiency    
Preferred Stock, $0.0001 par value; Authorized - 1,000,000 shares as of March 31, 2026 and December 31, 2025. Issued and outstanding – 147,512 as of March 31, 2026 and 147,512 shares as of December 31, 2025. 18,617 18,617
Common stock, $0.0001 par value (“Common Stock”); Authorized - 750,000,000 shares as of March 31, 2026 and December 31, 2025. Issued and outstanding – 6,543,703 and 1,593,703 as of March 31, 2026 and December 31, 2025, respectively. 7 7
Receivables on account of shares (3,300)
Additional paid-in capital 219,831 196,970
Accumulated deficit (236,036) (216,896)
Total capital deficiency (881) (1,302)
Total liabilities and capital deficiency $ 3,251 $ 5,783